ACT Post-Procedure Recovery: What to Expect in the Days and Weeks After | ALIV

Medically Reviewed by Dr. Sunita Tandulwadkar | Written by ALIV

The period after an ACT procedure is as important to understand as the procedure itself. Knowing what is normal, what requires attention, and when to expect any clinical response helps patients navigate the recovery period confidently and supports the best possible outcome from the biological process that the ACT preparation has initiated.

Immediate Post-Procedure Period (Day 0–3)

Harvest site: The bone marrow or adipose harvest site will be tender to touch and may have mild bruising over the following two to five days. A small sterile dressing is applied and should be kept dry for 48 hours. Mild paracetamol is appropriate for harvest site discomfort — avoid NSAIDs (ibuprofen, diclofenac) as these may inhibit the biological processes initiated by ACT. The administration site (joint, IV access, or intrathecal entry point) will be monitored before discharge and is typically minimally symptomatic beyond mild local tenderness.

The First Two Weeks: Systemic Response

The paracrine signalling initiated by ACT administration produces a systemic shift in the inflammatory and regenerative environment over the first two weeks. During this period, some patients experience: mild fatigue (often described as a "healing tiredness" — the body is upregulating repair processes); mild flu-like symptoms in the first 24–48 hours (transient inflammatory response as signalling cascades initiate); and occasionally a temporary worsening of the condition being treated before improvement begins — particularly in joint conditions, where the initial inflammatory response may temporarily increase pain before the anti-inflammatory shift takes effect. These responses are expected and do not require medical intervention in most cases. Contact ALIV immediately for: fever above 38.5°C; significant redness, warmth, or pus at the harvest site; rapidly increasing pain or swelling; or any symptom that feels disproportionate to what was described in this guide.

The Recovery and Response Timeline

Understanding when to expect clinical benefit helps patients persist through the early post-procedure period without prematurely concluding that the therapy has not worked. Initial responses — reduced systemic inflammatory burden, improved sleep, improved energy, and early reductions in pain — are typically first noticeable at two to six weeks post-procedure. More substantive functional improvements develop over three to six months as the paracrine regenerative processes produce cumulative tissue changes. Maximum benefit from a single ACT course is typically observed at six to twelve months post-procedure. See realistic outcome expectations: ACT results timeline.

What activities should I avoid after the procedure?

In the first week: avoid strenuous physical exercise, swimming (harvest site wound care), alcohol, smoking, and NSAIDs. In the first two weeks: avoid high-impact activities affecting the treated joint (for joint protocols) and continue to avoid NSAIDs and corticosteroids. From week three onwards: graduated return to normal activity, with specific guidance for joint loading or condition-specific exercise provided by ALIV's team. Smoking significantly impairs the regenerative response and cessation prior to and following ACT is strongly recommended.

Is it normal to feel worse in the first few days?

Temporary worsening — particularly of joint pain — in the first few days post-procedure is a recognised pattern in regenerative injection therapies, including both PRP and ACT. It reflects the acute inflammatory phase that precedes the anti-inflammatory shift. This pattern, where it occurs, typically resolves by day five to seven. Patients who have been warned about this in advance tolerate it much better than those for whom it is unexpected. It is not a sign of treatment failure and should not prompt intervention unless the symptoms are disproportionate (see the emergency guidance above).

Medically Reviewed by Dr. Sunita Tandulwadkar. This article is for informational purposes only and does not constitute medical advice. Therapies offered by ALIV are proprietary, experimental protocols and results vary by individual.